{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+0.9%25",
    "query": {
      "intervention": "Normal Saline 0.9%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1127,
    "total_pages": 113,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+Saline+0.9%25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T01:55:19.766Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02481869",
      "title": "Platelet Rich Plasma Injection in Pilon Fractures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fracture"
      ],
      "interventions": [
        {
          "name": "Arthrocentesis/PRP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Arthrocentesis/Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2015-06",
      "completion_date": "2019-11",
      "has_results": true,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481869"
    },
    {
      "nct_id": "NCT02169154",
      "title": "A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "1% Diclofenac Sodium",
          "type": "DRUG"
        },
        {
          "name": "3% Menthol",
          "type": "DRUG"
        },
        {
          "name": "0.09% Menthol",
          "type": "DRUG"
        },
        {
          "name": "0.2% Sodium Lauryl Sulfate",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2014-06-01",
      "completion_date": "2014-07-01",
      "has_results": false,
      "last_update_posted_date": "2017-06-29",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Paramus, New Jersey",
      "locations": [
        {
          "city": "Paramus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02169154"
    },
    {
      "nct_id": "NCT02266654",
      "title": "Early Goal Directed Therapy in Sepsis by Emergency Medical Services",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "IV fluids",
          "type": "OTHER"
        },
        {
          "name": "Hospital Notification",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-10",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02266654"
    },
    {
      "nct_id": "NCT02766673",
      "title": "Aerosolized Albuterol Use in Severe BPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Severe Bronchopulmonary Dysplasia"
      ],
      "interventions": [
        {
          "name": "Albuterol Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Sterile Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "Up to 1 Year"
      },
      "enrollment_count": 24,
      "start_date": "2016-08",
      "completion_date": "2018-06",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766673"
    },
    {
      "nct_id": "NCT04492475",
      "title": "Adaptive COVID-19 Treatment Trial 3 (ACTT-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 969,
      "start_date": "2020-08-05",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04492475"
    },
    {
      "nct_id": "NCT02377466",
      "title": "A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obstetric Labour, Premature"
      ],
      "interventions": [
        {
          "name": "Retosiban IV infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 45 Years · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2016-02-29",
      "completion_date": "2017-07-24",
      "has_results": true,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02377466"
    },
    {
      "nct_id": "NCT01170702",
      "title": "Transverse Abdominis Plane (TAP) Block After Cesarean Delivery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postoperative Pain",
        "Pregnancy",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "0.9% Normal Saline",
          "type": "DRUG"
        },
        {
          "name": "0.2% Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "0.5% Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "0.75% Ropivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2010-01",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170702"
    },
    {
      "nct_id": "NCT04722003",
      "title": "Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gonorrhoea"
      ],
      "interventions": [
        {
          "name": "Meningococcal Group B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 52,
      "start_date": "2021-11-01",
      "completion_date": "2023-10-02",
      "has_results": true,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04722003"
    },
    {
      "nct_id": "NCT05267886",
      "title": "CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Shock, Cardiogenic"
      ],
      "interventions": [
        {
          "name": "Dobutamine",
          "type": "DRUG"
        },
        {
          "name": "Milrinone",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ottawa Heart Institute Research Corporation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 346,
      "start_date": "2022-03-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267886"
    },
    {
      "nct_id": "NCT02823977",
      "title": "Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alcohol Withdrawal"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-02",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-19",
      "last_synced_at": "2026-09-19T01:55:19.766Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02823977"
    }
  ]
}